FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 10:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:42 AM
Filana rises after FDA lifts hold on epilepsy drug study
Brief: Filana Therapeutics - FDA Lifts Clinical Hold On Filana's Simufilam For TSC-Related Epilepsy
NASDAQ RESUMED AT 08:30 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Cassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing
Brief: Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing
Brief: Cassava Sciences To Offer Securities Up To $200 Million
Cassava Sciences Q3 net loss narrows, beats expectations
Brief: Cassava Sciences Q3 Basic EPS USD -0.22
Brief: Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Brief: Cassava Sciences Q2 Basic EPS USD -0.92
Brief: Cassava Sciences Appoints Dr. Joseph Hulihan As Chief Medical Officer
Brief: Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy